Ian Thomas Nisbet

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Meditech was an Australian biotechnology company focusing on the development of carbohydrate-based therapeutics. The company's platform technology HyACT™ was a drug-delivery technology shown to be highly effective in treating a variety of cancer types. The company was Located in Victoria, Australia.

ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia.

Prenolica Ltd. engages in the research and development of bio-medical products used in the treatment of cirrhosis, chronic hepatitis and other liver conditions. It products include Ropern, Tiga, Bio effective Gel and Siberian Red. The company was founded in 1995 and is headquartered in Melbourne, Australia.

Diversa Pty Ltd. engages in the provision of investment management and financial services. It operates through Superannuation Services and Trustee Services segments. The Superannuation Services segment provides administration and promotion services to superannuation funds and the issue of group risk products. The Trustee Services segment involves in the third party superannuation trustee services and investment services. The company was founded by Matthew Morgan and Angus Craig on July 03, 1997 and is headquartered in Melbourne, Australia.

ChemGenex Pharmaceuticals, Inc. manufactures and develops pharmaceuticals. It develops novel protein, antibody, & small molecule therapeutics in the areas of oncology, obesity, diabetes, and central nervous system disorders. The company is a subsidiary of Chemgenex Pharmaceuticals Ltd. It was founded in 2004 and is headquartered in Menlo Park, CA.

Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia.

Velacor Therapeutics Pty Ltd. develops novel therapeutics for prostate cancers. The firm offers novel treatment for prostate, glioblastoma, ovarian and lung cancer. The company was founded by Christopher Hovens in 2005 and is headquartered in Parkville, Australia.